Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  SciClone Pharmaceuticals, Inc.    SCLN

SummaryQuotesNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

SciClone to Restate Results for Certain Periods on China Accounting Errors

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/22/2013 | 11:05pm CET
   By Debbie Cai 
 

SciClone Pharmaceuticals Inc. (>> SciClone Pharmaceuticals, Inc.) said it will restate its financial statements for certain periods in 2012 and 2011 due mainly to accounting errors at a Chinese subsidiary.

Shares slid 6.2% to $4.52 after hours Friday. The stock is up 12% so far this year.

Chinese drugmaker NovaMed Pharmaceuticals Inc., which SciClone acquired in April 2011, made accounting errors pertaining to the timing of Pfizer Inc. (>> Pfizer Inc.) product-revenue recognition and the recognition of product-return reserves as to antiplatelet drug Aggrastat.

The company will restate financial statements for the first, second and third quarters of last year, the second and third quarters of 2011, and for the full 2011.

SciClone Chief Executive Friedhelm Blobel said the decision to restate financials, which is expected to increase the company's 2012 revenue and earnings and decrease that of 2011, was made after careful review of available facts.

The company believes the changes will raise its revenue for the first nine months of last year by about $3 million, and increase its profit before income taxes by about $2 million. The changes for the full 2011 will lower revenue by about $1 million and decrease income by less than $1 million.

SciClone also said the goodwill related to the acquisition of NovaMed will be increased by approximately $2 million. The restatements wouldn't impact previously reported cash or cash equivalents balances, the company said.

The company said it plans to amend its 2011 10-K form and other relevant filings as soon as reasonably practicable.

Last November, SciClone said it swung to a third-quarter loss as the company works to address issues across its China organization, some of which might have affected sales of its lead drug Zadaxin.

Write to Debbie Cai at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : SciClone Pharmaceuticals, Inc., Pfizer Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SCICLONE PHARMACEUTICALS,
10/17 SCICLONE PHARMACEUTICALS : Consortium Led By GL Capital Completes Acquisition of..
10/16 SCICLONE PHARMACEUTICALS, INC. (NASD : SCLN) Files An 8-K Completion of Acquisit..
10/13 SCICLONE PHARMACEUTICALS INC : Completion of Acquisition or Disposition of Asset..
10/13 SCICLONE PHARMACEUTICALS : Consortium Led By GL Capital Completes Acquisition Of..
09/28 SCICLONE PHARMACEUTICALS, INC. (NASD : SCLN) Files An 8-K Submission of Matters ..
09/27 SCICLONE PHARMACEUTICALS INC : Submission of Matters to a Vote of Security Holde..
08/29 Levi & Korsinsky, LLP Notifies Shareholders of SciClone Pharmaceuticals, Inc...
08/29 SCICLONE PHARMACEUTICALS : Corporate News Blog - Novo Nordisk’s Victoza(R)..
08/17 Monteverde & Associates PC Announces An Investigation Of SciClone Pharmaceuti..
08/17 SCICLONE PHARMACEUTICALS : Patent Issued for Treatment of Cancer with Immune Sti..
More news
News from SeekingAlpha
10/11 NMIH +5.3%, ACLS +4.6% on moves into SmallCap 600
08/09 SciClone Pharmaceuticals beats by $0.06, beats on revenue
06/09 RISK ARBITRAGE TODAY : Yahoo, Pandora And An M&A Fund That Has 20% In One Stock
06/08 HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am
06/08 PREMARKET GAINERS AS OF 9 : 05 am
Financials ($)
Technical analysis trends SCICLONE PHARMACEUTICALS,
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
 
Mean consensus
Number of Analysts
Average target price -
Spread / Average Target
EPS Revisions
Managers
NameTitle
Friedhelm Blobel President & Chief Executive Officer
Wai-Shun Cheung Chief Financial Officer & Senior VP-Finance
Ting Ping Ping Director
Carey Chern Secretary & Chief Compliance Officer
Lan Xie CFO-China Operations & Vice President-Finance
Sector and Competitors
1st jan.Capitalization (M$)
SCICLONE PHARMACEUTICALS, INC.3.24%0
JOHNSON & JOHNSON19.78%370 740
NOVARTIS11.20%219 321
PFIZER8.90%210 830
ROCHE HOLDING LTD.-1.55%200 193
MERCK AND COMPANY-6.23%150 550